文献速递肝病

质子泵抑制剂对肝硬化患者细胞色素P450活性的影响:13C-氨基比林呼气试验评估

Impact of proton pump inhibitors on cytochrome P450 activity assessed by 13 C-aminopyrine breath test in patients with cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2020-12-28

治疗第15天,奥美拉唑、埃索美拉唑和兰索拉唑组呼气试验指标较基线显著下降,而泮托拉唑和雷贝拉唑组无显著变化。提示在肝硬化患者中,泮托拉唑和雷贝拉唑对CYP450活性影响较小。

要点

  • 奥美拉唑、埃索美拉唑和兰索拉唑可显著抑制肝硬化患者CYP450活性。
  • 泮托拉唑和雷贝拉唑对肝硬化患者CYP450活性无显著影响。
  • 肝硬化患者需用PPI时,泮托拉唑或雷贝拉唑可能是更安全的选择。

核心结论

  • 在肝硬化患者中,奥美拉唑、埃索美拉唑和兰索拉唑抑制微粒体活性,而泮托拉唑和雷贝拉唑无显著影响。
  • 若数据在更大规模队列研究中得到证实,泮托拉唑和雷贝拉唑可安全推荐用于肝硬化患者。

研究设计与样本

  • 患者随机接受奥美拉唑20 mg/日、埃索美拉唑20 mg/日、兰索拉唑15 mg/日、泮托拉唑40 mg/日或雷贝拉唑20 mg/日。
  • 于基线和PPI治疗第15天进行13C-氨基比林呼气试验(13C-ABT)评估CYP450依赖性肝功能。

主要发现

  • 基线时,各组最大13C%剂量/小时和120分钟累积13C%剂量均无显著差异。
  • 治疗第15天,泮托拉唑组最大13C%剂量/小时和120分钟累积13C%剂量较基线无显著差异(P=0.184和P=0.309)。
  • 治疗第15天,雷贝拉唑组最大13C%剂量/小时和120分钟累积13C%剂量较基线无显著差异(P=0.536和P=0.286)。
  • 治疗第15天,奥美拉唑组最大13C%剂量/小时和120分钟累积13C%剂量较基线显著下降(P=0.013和P=0.015)。
  • 治疗第15天,埃索美拉唑组(P=0.009和P=0.001)和兰索拉唑组(P=0.033和P=0.035)最大13C%剂量/小时和120分钟累积13C%剂量较基线显著下降。

临床怎么用

  • 肝硬化患者需使用PPI时,可优先考虑泮托拉唑或雷贝拉唑,以减少对CYP450活性的抑制和潜在药物相互作用。
  • 奥美拉唑、埃索美拉唑和兰索拉唑可能抑制肝硬化患者CYP450活性,合用药时需警惕药物相互作用。

局限性

  • 研究对象仅限于HCV相关肝硬化患者,结果外推至其他病因肝硬化需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic use of proton pump inhibitors (PPIs) in patients with impaired liver function may worsen cytochrome P450 (CYP450) activity, predisposing them to clinically relevant drug-drug interactions. The 13 C-aminopyrine breath test (13 C-ABT) is a non-invasive tool to study CYP450-dependent liver function. AIMS: To assess 13 C-ABT modifications with different PPIs in patients with cirrhosis METHODS: Sixty consecutive patients with HCV-related cirrhosis and indication to start PPI therapy were randomised to receive omeprazole 20 mg/day, esomeprazole 20 mg/day, lansoprazole 15 mg/day, pantoprazole 40 mg/day or rabeprazole 20 mg/day. 13 C-ABT was performed at baseline and on the 15th day of PPI therapy. RESULTS: At baseline, mean values of max 13 C% dose/h and 13 C% cum dose at 120 minutes did not differ significantly among groups. On the 15th day of therapy, max 13 C% dose/h and 13 C% cum dose at 120 minutes did not significantly differ with respect to baseline for pantoprazole (P = 0.184 and P = 0.309, respectively) or rabeprazole (P = 0.536 and P = 0.286, respectively), but were significantly decreased on omeprazole (P = 0.013 and P = 0.015, respectively), esomeprazole (P = 0.009 and P = 0.001, respectively), and lansoprazole (P = 0.033 and P = 0.035, respectively). CONCLUSIONS: In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact. Should our data be confirmed in larger cohort studies, pantoprazole and rabeprazole could be safely recommended for patients with cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rocco A, Compare D, Sgamato C, et al. Impact of proton pump inhibitors on cytochrome P450 activity assessed by 13 C-aminopyrine breath test in patients with cirrhosis. Aliment Pharmacol Ther. 2020. PMID: 33368499. doi:10.1111/apt.16239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。